Trial · NCT02760069
Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
NCT02760069, Phase 4, Completed, Brooke Army Medical Center; results first posted 2020-07-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department. Trials, record NCT02760069. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02760069
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
- NCT number
- NCT02760069
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 122 participants, actual
- Lead sponsor
- Brooke Army Medical Center
- Conditions
- Nausea
- Interventions
- Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
- First posted
- 2016-05-03
- Last updated
- 2020-07-23
- Results first posted
- 2020-07-23
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Nausea 100 mm Visual Analogue Scale (VAS) | 30 minutes post intervention | Full Scale Name: Nausea 100-mm visual analogue scale. Scale Construct: Measures nausea as reported by the patient Scale Range: Minimum is 0 (no nausea) to 100 (worst nausea imaginable). These values quantify, on an interval scale anchored at 0, the patient's subjective sensation of nausea. Higher values represent worse outcomes (e.g., more nausea). Patient makes a single vertical mark on a 100 mm horizontal line with 0 at the left and 100 on the right to depict their nausea. |
| Secondary | Number of Participants Who Required Rescue Anti-emetics | Study duration (up to 5 hours post intervention) | Whether patient required rescue anti-emetics (binary variable). Measured using nurse drug administration record. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Nausea 100 mm Visual Analogue Scale (VAS) | 30 minutes post intervention | units on a scale | MEAN | |
| SECONDARY | Number of Participants Who Required Rescue Anti-emetics | Study duration (up to 5 hours post intervention) | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Nausea 100 mm Visual Analogue Scale (VAS) | Inhaled ISO + Oral Ondansetron | 23 | Standard Deviation 25 | units on a scale | |
| Nausea 100 mm Visual Analogue Scale (VAS) | Inhaled ISO + Oral Placebo | 19 | Standard Deviation 18 | units on a scale | |
| Nausea 100 mm Visual Analogue Scale (VAS) | Inhaled Placebo + Oral Ondansetron | 42 | Standard Deviation 27 | units on a scale | |
| Number of Participants Who Required Rescue Anti-emetics | Inhaled ISO + Oral Ondansetron | 11 | Participants | ||
| Number of Participants Who Required Rescue Anti-emetics | Inhaled ISO + Oral Placebo | 10 | Participants | ||
| Number of Participants Who Required Rescue Anti-emetics | Inhaled Placebo + Oral Ondansetron | 18 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Inhaled ISO + Oral Ondansetron | 40 | |
| Overall Study | STARTED | Inhaled ISO + Oral Placebo | 41 | |
| Overall Study | STARTED | Inhaled Placebo + Oral Ondansetron | 41 | |
| Overall Study | COMPLETED | Inhaled ISO + Oral Ondansetron | 40 | |
| Overall Study | COMPLETED | Inhaled ISO + Oral Placebo | 40 | |
| Overall Study | COMPLETED | Inhaled Placebo + Oral Ondansetron | 40 | |
| Overall Study | NOT COMPLETED | Inhaled ISO + Oral Ondansetron | 0 | |
| Overall Study | NOT COMPLETED | Inhaled ISO + Oral Placebo | 1 | |
| Overall Study | NOT COMPLETED | Inhaled Placebo + Oral Ondansetron | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Inhaled ISO + Oral Ondansetron | 0 | 40 |
| Total, all-cause mortality | Inhaled ISO + Oral Placebo | 0 | 40 |
| Total, all-cause mortality | Inhaled Placebo + Oral Ondansetron | 0 | 40 |
| Total, other adverse events | Inhaled ISO + Oral Ondansetron | 0 | 40 |
| Total, other adverse events | Inhaled ISO + Oral Placebo | 0 | 40 |
| Total, other adverse events | Inhaled Placebo + Oral Ondansetron | 0 | 40 |
| Total, serious adverse events | Inhaled ISO + Oral Ondansetron | 0 | 40 |
| Total, serious adverse events | Inhaled ISO + Oral Placebo | 0 | 40 |
| Total, serious adverse events | Inhaled Placebo + Oral Ondansetron | 0 | 40 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02760069
GET https://conductscience.org/api/trials/v1/NCT02760069/registered